62,445 Shares in Phreesia, Inc. (NYSE:PHR) Purchased by Calamos Advisors LLC

Calamos Advisors LLC acquired a new position in Phreesia, Inc. (NYSE:PHR - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 62,445 shares of the company's stock, valued at approximately $1,596,000. Calamos Advisors LLC owned about 0.11% of Phreesia at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Deerfield Management Company L.P. Series C lifted its holdings in Phreesia by 133.6% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 1,271,832 shares of the company's stock valued at $31,999,000 after purchasing an additional 727,384 shares in the last quarter. Greenhouse Funds LLLP lifted its holdings in Phreesia by 27.9% during the fourth quarter. Greenhouse Funds LLLP now owns 2,873,892 shares of the company's stock valued at $72,307,000 after purchasing an additional 626,579 shares in the last quarter. Park West Asset Management LLC purchased a new position in Phreesia during the fourth quarter valued at approximately $10,657,000. Millennium Management LLC lifted its holdings in Phreesia by 83.2% during the fourth quarter. Millennium Management LLC now owns 653,634 shares of the company's stock valued at $16,445,000 after purchasing an additional 296,863 shares in the last quarter. Finally, ExodusPoint Capital Management LP lifted its holdings in Phreesia by 448.6% during the fourth quarter. ExodusPoint Capital Management LP now owns 174,971 shares of the company's stock valued at $4,402,000 after purchasing an additional 143,077 shares in the last quarter. Hedge funds and other institutional investors own 92.10% of the company's stock.

Insider Buying and Selling at Phreesia

In other Phreesia news, Director Michael Weintraub sold 7,431 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $27.51, for a total transaction of $204,426.81. Following the completion of the transaction, the director owned 143,039 shares in the company, valued at $3,935,002.89. The trade was a 4.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP David Linetsky sold 23,729 shares of the company's stock in a transaction dated Friday, June 27th. The stock was sold at an average price of $28.50, for a total transaction of $676,276.50. Following the completion of the sale, the senior vice president directly owned 193,510 shares of the company's stock, valued at approximately $5,515,035. This trade represents a 10.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 54,781 shares of company stock valued at $1,504,911. Insiders own 5.50% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on PHR shares. DA Davidson lowered their price target on shares of Phreesia from $36.00 to $34.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Truist Financial lifted their price target on shares of Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a report on Thursday, May 29th. Canaccord Genuity Group reduced their price objective on shares of Phreesia from $35.00 to $34.00 and set a "buy" rating on the stock in a research report on Thursday, May 29th. Needham & Company LLC reiterated a "buy" rating and set a $29.00 price objective on shares of Phreesia in a research report on Thursday, March 13th. Finally, KeyCorp reduced their price objective on shares of Phreesia from $30.00 to $28.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 16th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Phreesia has an average rating of "Buy" and an average price target of $31.64.

Phreesia Price Performance

PHR traded down $0.28 during trading hours on Thursday, hitting $28.68. The company's stock had a trading volume of 288,849 shares, compared to its average volume of 457,749. The business's 50-day moving average price is $26.25 and its 200-day moving average price is $26.32. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $30.53. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of -38.76 and a beta of 0.72. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.02.

Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.06. Phreesia had a negative net margin of 9.83% and a negative return on equity of 16.23%. The company had revenue of $115.94 million for the quarter, compared to analysts' expectations of $115.00 million. During the same quarter in the previous year, the business posted ($0.05) earnings per share. Phreesia's quarterly revenue was up 14.5% on a year-over-year basis. Sell-side analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.